109 Dyr1ka Inhibition for Glioblastoma Treatment: A DREAM-Centric Approach to Cell Cycle Inhibition With Immune Implications

View at publisher Summarise with VIRAT
Authors: Jacob Young, Pavlina Chuntova, Bjoern Schwer
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Dysregulated cell proliferation is a hallmark of glioblastoma and DYRK1A kinase, a key cell cycle regulator, may provide a therapeutic target for this devastating disease. METHODS: Novel small-molecule inhibitors of DYRK1A were developed and explored against SB28 mouse glioblastoma cells in vitro and in vivo. We performed incucyte live-cell imaging analysis and CellTiter cell proliferation assays to test the impact of these small molecule inhibitors in isolation and in combination with other chemotherapeutics and small molecule inhibitors. Cell size and morphology was assessed with fluorescent microscopy. Bulk RNA-sequencing and multiplexed cytokine arrays were used to measure gene expression changes and alterations in cytokine secretion. A pilot in vivo experiment was performed in immunocompetent tumor bearing mice to explore the biological and therapeutic effect of these novel agents. RESULTS: Treating SB28 cells with Dyrk1a inhibitors decreases cell proliferation, alters cell morphology, and increases nuclear size. Cell proliferation assays identified an IC50 in the micromolar range and there is a synergistic effect on cell proliferation when DRYK1A inhibition is combined with TMZ or CDK4/6 inhibitors. DRY1A treated cells are stuck in the G2 phase of the cell cycle based on flow cytometry. Dyrk1a treatment altered the profile of secreted cytokines from SB28 tumors in vitro and KEGG pathway analysis on bulk RNA-seq data suggested changes in cellular senescence genes after treatment. Immunocompetent mice (n=8-10/group) bearing SB28 allografts (1x104 cells) treated with the DRYK1A inhibitor, LCTB-1 (10 mg/kg daily via oral gavage), had a transient decrease in tumor size as measured with bioluminescence and animals maintained their normal body weight for longer compared to animals in the control group. CONCLUSIONS: DRYK1A inhibition slows glioblastoma cell proliferation, stalls cells in G2 phase of cell division and alters gene expression and cytokine release. This is a promising target to combine with other targeted inhibitors of cell proliferation and immunotherapy agents.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Cancer Mechanisms and Therapy Cancer-related Molecular Pathways

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
13–14
Publication date
26 March 2026
Language
EN